In this phase III study and its associated extension study, 257 patients with polycythemia vera (PV) were randomized to receive a monopegylated interferon, ropeginterferon alfa-2b, or hydroxyurea. Throughout the extension study, use of ropeginterferon compared with hydroxyurea was associated with a greater incidence of complete hematologic response along with an improved disease burden (at 36 months, 53% vs 38%; P=.044) and complete hematologic response alone (71% vs 51%; P=.012). Both treatments were well-tolerated.
In patients with early PV with splenomegaly, ropeginterferon alfa-2b was not noninferior to hydroxyurea at 12 months, but it did show improved responses at 36 months, with good tolerability.
« The increasing rate of complete hematologic response over time with ropeginterferon alfa-2b, coupled with the high frequency of molecular response, suggests that this agent has potential activity against progression of PV. If made available, ropeginterferon alfa-2b will provide a formidable frontline alternative to hydroxyurea in PV patients requiring cytoreduction »
You get higher and more constant level of circulating INF with ropeginterferon, that’s why it’s potentially more effective on the long term compared to Pegasys.
Hello yes I was on hydroxyurea for 6 years. First started on 500 mg, then 1000 and ended on 1500 mg. My experience was a lot of bone pain once I had to take 1500 mg a day. Brain fog so much I had to retire early at age 57. No weight gain for me or nausea with it. Hope this helps.
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.